Dr Charles Harrington
BSc (Hons) (Glasgow, 1977); PhD (Glasgow, 1980)
Senior Research Fellow
Charlie Harrington graduated in Microbiology from Glasgow University where he developed an interest in chemical microbiology and the study of microbial cell walls. He continued with his PhD working with Dr Julia Douglas on the regulation of cell wall synthesis in yeast. This was followed by a one-year NIH-funded Fellowship with Dr Wilf Arnold in Kansas City, Missouri studying enzymes within the yeast cell envelope. After this, Charlie joined Professor Sir James Baddiley in the Department of Biochemistry at the University of Cambridge as a Research Fellow. He spent four years studying the synthesis of cell wall polymers, this time those in bacteria. Dr Harrington then spent over two years in research and development at Murex Medical Research Ltd., Cambridge, developing diagnostic tests for microbial diseases, including methicillin-resistant Staphylococcus aureus and sexually transmitted diseases. This combined monoclonal antibody technology with his knowledge of the microbial cell surface.
In 1988, he joined Claude Wischik working at the Medical Research Council’s Laboratory of Molecular Biology to develop diagnostic tests for Alzheimer’s disease. Working in the Cambridge Brain Bank Laboratory over a period of 10 years, he was supported by the Medical Research Council, ICI Ltd. and a Newton Trust Research Fellowship from Trinity College. During this time, Wischik, Harrington and colleagues developed an assay for screening agents having the potential to prevent the tau pathology that is the hallmark of Alzheimer’s disease. Charlie moved with Professor Wischik, in 1998, to the University of Aberdeen, where he was appointed a Senior Research Fellow in the Department of Mental Health.
Research was translated to the clinic, with a phase 2 trial in Alzheimer's disease completed in 2008 and phase 3 trials completed in 2016. Dr Harrington is Chief Scientific Officer for TauRx Therapeutics Ltd.
Dr Harrington has research interests in the neurodegenerative diseases and, in particular, Alzheimer’s disease. His main focus has been on the biology of tau protein in aging and in Alzheimer’s disease. Dr Harrington’s research is aimed at diseases that are characterised by protein aggregation and methods by which these processes might be prevented.
Page 1 of 8 Results 1 to 10 of 78
Proteomic analysis of hydromethylthionine in the line 66 model of frontotemporal dementia demonstrates actions on tau-dependent and tau-independent networksCells, vol. 10, no. 8, 2162Contributions to Journals: Articles
Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementiaBrain CommunicationsContributions to Journals: Articles
Tau Protein Phosphorylated at Threonine-231 Is Expressed Abundantly in the Cerebellum in Prion EncephalopathiesJournal of Alzheimer's Disease, vol. 81, no. 2, pp. 769-785Contributions to Journals: Articles
Elucidating the neuropathologic mechanisms of SARS-CoV-2 infectionFrontiers in Neurology, vol. 12, 660087Contributions to Journals: Articles
Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer’s Disease BrainsInternational Journal of Molecular Sciences, vol. 22, no. 7, 3654Contributions to Journals: Articles
Oxidative Stress Conditions Result in Trapping of PHF-Core Tau (297–391) IntermediatesCells, vol. 10, no. 3, 703Contributions to Journals: Articles
The Neurovascular Unit Dysfunction in Alzheimer's DiseaseInternational Journal of Molecular Sciences, vol. 22, no. 4, 2022Contributions to Journals: Review articles
Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial DegenerationJournal of Alzheimer's Disease, vol. 79, no. 4, pp. 1517-1531Contributions to Journals: Articles
Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the Line 66 model of frontotemporal dementiaJournal of Biological Chemistry, vol. 295, no. 52, pp. 18508-18523Contributions to Journals: Articles
Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer’s DiseaseInternational Journal of Molecular Sciences, vol. 21, no. 22, pp. 1-19Contributions to Journals: Articles